CellSource Co., Ltd. (4880) AI Stock Analysis

• Market Cap: ¥13.87B
• Dividend Yield: 0.71%
• Average Volume (3M): 39.62K
• Price to Earnings (P/E): 284.5
• Beta (1Y): 0.64
• Revenue Growth: -13.57%
• EPS Growth: -106.11%
• Country: JP
• Employees: 151
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): 2.86
• Shares Outstanding: 19,816,362
• 10 Day Avg. Volume: 45,670
• 30 Day Avg. Volume: 39,623
• PEG Ratio: -3.46
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥743.00
• Price Target Upside: 6.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ¥786.00 ▲(12.29%Upside)

CellSource Co., Ltd. benefits from a strong financial position and positive cash flow generation, which are significant strengths. However, the stock's valuation is a major concern due to a negative P/E ratio, indicating potential profitability issues. Technical indicators suggest moderate bullish momentum, but overall, the stock presents mixed signals with more weight on financial stability.

CellSource Co., Ltd. Business Overview & Revenue Model

Company Description

CellSource Co., Ltd. (4880) is a biotechnology company specializing in regenerative medicine and cell therapy solutions. The company focuses on the development and commercialization of cutting-edge treatments using stem cell technology, particularly for diseases and conditions that currently have limited therapeutic options. Their core services include the collection, processing, and storage of stem cells, as well as research and development of new regenerative therapies.

How the Company Makes Money

CellSource Co., Ltd. generates revenue primarily through its stem cell processing and storage services, where clients pay for the collection, processing, and long-term storage of their stem cells for potential future medical use. Additionally, the company earns income through partnerships with healthcare institutions and research organizations for the development and commercialization of new regenerative medicine products. Revenue is also bolstered by licensing agreements for their proprietary technologies and solutions in the field of regenerative medicine.

CellSource Co., Ltd. Financial Statement Overview

Summary

CellSource Co., Ltd. has demonstrated stable revenue growth and effective cost management with a strong equity position. However, recent declines in net income and revenue growth pose challenges. Despite this, low leverage and solid cash flow generation provide stability.

Income Statement

CellSource Co., Ltd. has shown a consistent increase in total revenue over the years, demonstrating strong growth in the biotechnology sector. However, the latest year saw a slight decline in revenue. The gross profit margin is solid, indicating efficient cost management. The company has maintained a healthy net profit margin, although it has decreased recently due to lower net income. Overall, the income statement reflects a stable revenue base with some recent challenges in profitability.

Balance Sheet

The company's balance sheet reveals a robust financial position with a strong equity base and minimal debt, reflected in a low debt-to-equity ratio. The equity ratio is high, indicating a well-capitalized structure. Return on equity has decreased, correlating with the drop in net income, but remains positive. Overall, the balance sheet reflects financial stability and low leverage risk.

Cash Flow

CellSource has generated consistent operating cash flow, supporting its operations. Free cash flow has been positive, though its growth has been moderate recently. The operating cash flow to net income ratio is healthy, suggesting effective cash management. However, the recent decline in free cash flow growth highlights potential challenges in sustaining cash flow growth. Overall, the cash flow statement indicates solid cash generation with room for improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.36B	4.51B	4.27B	2.92B	1.86B
Gross Profit	2.42B	3.18B	3.06B	2.07B	1.26B
EBITDA	449.53M	1.31B	1.64B	1.06B	476.46M
Net Income	237.94M	923.14M	1.02B	651.40M	274.08M
Balance Sheet
Total Assets	7.07B	6.88B	4.60B	3.37B	2.35B
Cash, Cash Equivalents and Short-Term Investments	4.32B	4.78B	3.12B	2.41B	1.76B
Total Debt	77.29M	97.54M	0.00	1.10M	4.29M
Total Liabilities	1.04B	677.74M	814.15M	645.00M	309.63M
Stockholders Equity	6.04B	6.20B	3.79B	2.72B	2.04B
Cash Flow
Free Cash Flow	52.04M	487.69M	748.44M	836.74M	297.50M
Operating Cash Flow	591.72M	846.69M	847.60M	898.19M	330.23M
Investing Cash Flow	-614.96M	-624.08M	-169.39M	-256.12M	-57.83M
Financing Cash Flow	-437.24M	1.45B	14.42M	9.35M	152.65M

CellSource Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 700.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Neutral. The current price of 700 is above the 20-day moving average (MA) of 687.30, above the 50-day MA of 685.48, and below the 200-day MA of 845.38, indicating a neutral trend. The MACD of 3.58 indicates Negative momentum. The RSI at 51.11 is Neutral, neither overbought nor oversold. The STOCH value of 53.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4880.

CellSource Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	69 Neutral	¥13.87B	284.55		0.71%	-13.57%	-106.11%
7096	67 Neutral	¥10.45B	27.08		―	7.98%	24.12%
4888	55 Neutral	¥13.72B	―		―	256.62%	81.71%
Sector *	50 Neutral	AU$2.64B	3.32	-57.47%	2.62%	36.37%	14.48%
4978	49 Neutral	¥20.47B	206.40		―	8.46%	49.97%
4599	47 Neutral	¥19.20B	―		―	-100.00%	-1079.89%
7776	46 Neutral	¥16.57B	―		―	-4.04%	-0.88%

CellSource Co., Ltd. Corporate Events

CellSource Announces Leadership Change to Drive Expansion

CellSource Co., Ltd. announced a leadership change, with Masayuki Yamakawa, a co-founder and medical doctor, taking over as Representative Director and CEO from Takashi Sawada. This transition aims to leverage the company’s robust management structure for significant expansion in regenerative medicine and self-funded healthcare, marking a shift to a more proactive management approach.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports Growth in June 2025 Contract Processing Orders

CellSource Co., Ltd. reported a notable increase in its daily average number of contract processing orders for June 2025, driven by a significant rise in blood-derived orders from its hybrid orthopedics segment. The company continues to strengthen its operations in self-funded orthopedics and hybrid orthopedics, with a focus on maintaining order volumes and expanding partnerships with key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Finalizes Stock Option Terms

CellSource Co., Ltd. has finalized the terms for its stock acquisition rights, initially resolved at a Board of Directors meeting on June 12, 2025. The finalized terms involve two employees receiving a total of 1,582 stock acquisition rights, with an exercise price set at 68,200 yen per right, equivalent to 682 yen per share.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen880.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Announces Six-Month Financial Results and Full-Year Forecast

CellSource Co., Ltd. reported its consolidated financial results for the six months ended April 30, 2025, under Japanese GAAP. The company achieved net sales of ¥1,820 million and a profit attributable to owners of ¥11 million. The equity-to-asset ratio stood at 85.1%, reflecting a strong financial position. The company has transitioned to consolidated accounting from the fiscal year ending October 31, 2025, which impacts the comparability of year-on-year changes. The financial forecast for the full year ending October 31, 2025, projects net sales of ¥4,501 million and a profit attributable to owners of ¥255 million.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Issues Stock Options to Employees to Boost Corporate Value

CellSource Co., Ltd. has announced the issuance of stock options to its employees, aimed at boosting corporate value and improving performance over the medium to long term. The issuance involves 1,582 stock acquisition rights, which, if fully exercised, will result in a maximum dilution of 0.8% of the total issued shares. The company believes this move will enhance shareholder value and considers the dilution impact to be within a reasonable range.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports Stable April 2025 KPI Results Amid Strategic Focus

CellSource Co., Ltd. reported its April 2025 KPI results, highlighting a stable daily average of processing orders at 58.5, consistent with March figures. Despite a slight decrease in orders for adipose-derived stem cell processing and non-orthopedic departments, the company maintained a steady number of blood-derived processing orders in its core orthopedic segment. The company noted a decrease in monthly orders for blood-derived products in both self-funded and hybrid orthopedics, with a 2.7% and 2.0% decline, respectively. However, they are focusing on strengthening their organizational structure and maintaining planned order volumes, while ongoing initiatives target key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.